driven by the PitchBook Platform
June 10, 2010
Avista Capital Partners has made a $48.5 million growth investment in OptiNose to help the company bring to market its new nasal drug delivery device. The company has previously raised venture financing from a group of VC investors, including Entrepreneurs Fund, inSpire Ventures and WFD Ventures.
2017
September 18, 2017
3Q 2017
September 14, 2017
